These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 10211916)

  • 21. Relationship of serum haloperidol levels to clinical response in schizophrenic patients.
    Magliozzi JR; Hollister LE; Arnold KV; Earle GM
    Am J Psychiatry; 1981 Mar; 138(3):365-7. PubMed ID: 7468835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interaction between fluoxetine and haloperidol: pharmacokinetic and clinical implications.
    Avenoso A; Spinà E; Campo G; Facciolă G; Ferlito M; Zuccaro P; Perucca E; Caputi AP
    Pharmacol Res; 1997 Apr; 35(4):335-9. PubMed ID: 9264051
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of rifampin on the plasma concentration and the clinical effect of haloperidol concomitantly administered to schizophrenic patients.
    Kim YH; Cha IJ; Shim JC; Shin JG; Yoon YR; Kim YK; Kim JI; Park GH; Jang IJ; Woo JI; Shin SG
    J Clin Psychopharmacol; 1996 Jun; 16(3):247-52. PubMed ID: 8784658
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of subtle neurological dysfunction on response to haloperidol treatment in schizophrenia.
    Convit A; Volavka J; Czobor P; de Asis J; Evangelista C
    Am J Psychiatry; 1994 Jan; 151(1):49-56. PubMed ID: 8267134
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The relationship of haloperidol concentrations to therapeutic response.
    Perry PJ; Pfohl BM; Kelly MW
    J Clin Psychopharmacol; 1988 Feb; 8(1):38-43. PubMed ID: 3350997
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma haloperidol levels and therapeutic response in acute mania and schizophrenia.
    Balant-Gorgia AE; Eisele R; Balant L; Garrone G
    Eur Arch Psychiatry Neurol Sci; 1984; 234(1):1-4. PubMed ID: 6489392
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intensive treatment with haloperidol of treatment-resistant chronic schizophrenic patients.
    Hollister LE; Kim DY
    Am J Psychiatry; 1982 Nov; 139(11):1466-8. PubMed ID: 7137396
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients.
    Roh HK; Chung JY; Oh DY; Park CS; Svensson JO; Dahl ML; Bertilsson L
    Br J Clin Pharmacol; 2001 Sep; 52(3):265-71. PubMed ID: 11560558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. No pharmacokinetic but pharmacodynamic interactions between cisapride and bromperidol or haloperidol.
    Mihara K; Otani K; Yasui N; Ishida M; Kondo T; Suzuki A; Furukori H; Nagashima U; Kaneko S; Inoue Y
    Ther Drug Monit; 1999 Jun; 21(3):297-300. PubMed ID: 10365640
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Haloperidol and reduced haloperidol concentrations in plasma and red blood cells from chronic schizophrenic patients.
    Ko GN; Korpi ER; Kirch DG
    J Clin Psychopharmacol; 1989 Jun; 9(3):186-90. PubMed ID: 2661607
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole.
    Varis T; Kaukonen KM; Kivistö KT; Neuvonen PJ
    Clin Pharmacol Ther; 1998 Oct; 64(4):363-8. PubMed ID: 9797792
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole.
    Kivistö KT; Lamberg TS; Kantola T; Neuvonen PJ
    Clin Pharmacol Ther; 1997 Sep; 62(3):348-54. PubMed ID: 9333111
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RBC and plasma levels of haloperidol and clinical response in schizophrenia.
    Smith RC; Vroulis G; Shvartsburd A; Allen R; Lewis N; Schoolar JC; Chojnacki M; Johnson R
    Am J Psychiatry; 1982 Aug; 139(8):1054-6. PubMed ID: 7091432
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Involvement of CYP3A4 in the metabolism of bromperidol in vitro.
    Sato S; Someya T; Shioiri O; Koitabashi T; Inoue Y
    Pharmacol Toxicol; 2000 Mar; 86(3):145-8. PubMed ID: 10752674
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Haloperidol plasma levels and dose optimization.
    Coryell W; Miller DD; Perry PJ
    Am J Psychiatry; 1998 Jan; 155(1):48-53. PubMed ID: 9433338
    [TBL] [Abstract][Full Text] [Related]  

  • 37. No interaction between desipramine and bromperidol.
    Suzuki A; Otani K; Ishida M; Yasui N; Kondo T; Mihara K; Kaneko S; Inoue Y
    Prog Neuropsychopharmacol Biol Psychiatry; 1996 Oct; 20(7):1265-71. PubMed ID: 8938825
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sulpiride and haloperidol in schizophrenia: a double-blind cross-over study of therapeutic effect, side effects and plasma concentrations.
    Gerlach J; Behnke K; Heltberg J; Munk-Anderson E; Nielsen H
    Br J Psychiatry; 1985 Sep; 147():283-8. PubMed ID: 3904885
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An open trial of buspirone added to neuroleptics in schizophrenic patients.
    Goff DC; Midha KK; Brotman AW; McCormick S; Waites M; Amico ET
    J Clin Psychopharmacol; 1991 Jun; 11(3):193-7. PubMed ID: 2066458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical response and plasma haloperidol levels in chronic and subchronic schizophrenia.
    Santos JL; Cabranes JA; Vazquez C; Fuentenebro F; Almoguera I; Ramos JA
    Biol Psychiatry; 1989 Aug; 26(4):381-8. PubMed ID: 2669981
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.